[Orimeten in the treatment of advanced carcinoma of the prostate].
The authors treated 16 patients with advanced prostate carcinoma after previous orchiectomy and further progression of the disease: 9 patients with Cyclophosphamide + Ftorafur + placebo and seven patients with Cyclophosphamide + Ftorafur + Orimeten. They achieved in particular improvement of the subjective complaints, while in both groups there was objective progression of the disease. In the group with Orimeten the objective progression of the disease was slower than in the group where cytostatics alone were administered.
Vachalovský
V
V
Vomácka
V
V
D000368:Aged; D000369:Aged, 80 and over; D000616:Aminoglutethimide / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage
D000970:Antineoplastic Agents; D000616:Aminoglutethimide; D005641:Tegafur; D003520:Cyclophosphamide
Orimeten v lécbĕ pokrocilého karcinomu prostaty.